. 2023 May 2;6(5):e2311181. doi: 10.1001/jamanetworkopen.2023.11181

Table 2. Statistical Summary of the Association of TMB With Clinical Outcomes.

Cohort	Model	End point	TMB, HR	1-Sided UCB	P value
All evaluable	Univariate	OS	0.72	0.91	.01
Prospective	Univariate	OS	0.61	0.84	.005
Prospective	Univariate	PFS	0.62	0.82	.003
Prospective	Univariate	TTP	0.67	0.92	.02
Prospective pembrolizumab treated	Univariate	OS	0.67	0.94	.03
Prospective nonpembrolizumab treated	Univariate	OS	0.37	0.85	.03
Prospective	Multivariable^a	OS	0.67	0.92	.02

Abbreviations: OS, overall survival; PFS, progression-free survival; TMB, tumor mutational burden; TTP, time to progression; UCB, upper confidence bound.

^{^a}

In the multivariable model, the variables tested for association with OS are TMB, programmed cell death-ligand 1 status (positive/negative/unknown) and microsatellite instability status (high vs low).